MacroGenics registers Phase 1 first-in-human trial of ADC MGC030 in solid tumors
MacroGenics has listed a new Phase 1 study of its antibody-drug conjugate MGC030 across six tumor types, not yet recruiting.
MacroGenics posted one new clinical trial registration during the week.
- MGC030, described as an antibody-drug conjugate1, is being tested in a Phase 1, first-in-human study for participants with advanced solid tumors, evaluating safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor activity1. The trial (NCT07822399) is not yet recruiting, with an estimated start of September 2026 and estimated primary completion in September 20281, and plans to enroll 314 participants1 across Urothelial Cancer, GastroEsophageal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), and Pancreatic Cancer1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.